Primary Myelofibrosis: Clinical Trials

199 trials for Primary Myelofibrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

95 completed, 35 recruiting, 30 terminated, 17 active not recruiting. 199 Phase 1, 66 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1199Completed 95, Recruiting 35, Terminated 30, Active not recruiting 17, Withdrawn 10, Unknown 9, Not yet recruiting 2, Suspended 1
Phase 266Completed 32, Recruiting 12, Terminated 10, Unknown 4, Withdrawn 4, Active not recruiting 2, Not yet recruiting 1, Suspended 1

Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis

Trials (filtered) newest first · largest first

All 199 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation
Phase 1Not yet recruitingUniversity of Wisconsin, Madison272027-02-012026-11-02
Revumenib in Patients With Myelofibrosis
Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 1 / Phase 2Not yet recruitingJohn Mascarenhas322026-12-012026-07-29
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis
Phase 1 / Phase 2RecruitingRuijin Hospital102026-10-152026-10-28
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Phase 1RecruitingCity of Hope Medical Center462026-09-092026-10-23
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs)
Phase 1RecruitingDamora Therapeutics2502026-09-012026-10-27
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis
Phase 1RecruitingUniversity of Utah152026-08-212026-10-19
QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets - Myelofibrosis
Phase 1Active not recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.602026-07-302026-08-07
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT)
Phase 1RecruitingStanford University502026-07-212026-08-17
Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets
TQ05105 tablets, Rabeprazole sodium enteric-coated tablets - Myelofibrosis
Phase 1Active not recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.172026-07-202026-07-27
Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders
ZE74-0282 - Polycythemia Vera (PV), Myelofibrosis (MF)
Phase 1RecruitingEilean Therapeutics602026-06-012026-11-12
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
rebecsinib - Secondary AML, Myelofibrosis
Phase 1RecruitingAspera Biomedicines, Inc.282026-05-212026-07-20
Therapeutic RSK1 Targeting in Myeloid Malignancies
PMD-026 - Myeloid Malignancy
Phase 1RecruitingWashington University School of Medicine302026-05-202026-10-21
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation2182026-05-112026-11-13
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
PRT12396 - Polycythemia Vera (PV), Myelofibrosis (MF)
Phase 1RecruitingPrelude Therapeutics Incorporated1002026-04-292026-10-29
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
ZE74-0282-0001 or placebo - Healthy Volunteers
Phase 1RecruitingEilean Therapeutics AU Pty Ltd642026-04-162026-07-28
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Pelabresib, Ruxolitinib - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Phase 1Active not recruitingNovartis Pharmaceuticals32026-04-152026-09-09
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
TQ05105 - Myelofibrosis
Phase 1RecruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.242026-04-012026-04-06
Momelotinib During and After HCT in Myelofibrosis
Momelotinib - Myelofibrosis, Hematopoietic Cell Transplantation (HCT)
Phase 1RecruitingMassachusetts General Hospital282026-02-232026-03-31
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Axatilimab (SNDX-6352), Ruxolitinib - Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center662026-01-022026-10-09
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Roginolisib - Myelofibrosis (MF)
Phase 1 / Phase 2RecruitingiOnctura262025-11-172026-06-23

Showing 20 of 199. Sign in to see all of them.

Narrower conditions

Myeloproliferative Disorders (87)  ·  Leukemia, Myeloid, Acute (76)  ·  Myelodysplastic Syndromes (69)  ·  Thrombocythemia, Essential (61)  ·  Leukemia, Myelomonocytic, Chronic (60)  ·  Polycythemia Vera (60)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (59)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (54)  ·  Lymphoma, Non-Hodgkin (48)  ·  Multiple Myeloma (48)  ·  Leukemia (47)  ·  Hodgkin Disease (42)  ·  Lymphoma, Follicular (41)  ·  Lymphoma, Large B-Cell, Diffuse (41)

Broader conditions

Hemic and Lymphatic Diseases (199)  ·  Bone Marrow Diseases (194)  ·  Hematologic Diseases (193)  ·  Neoplasms (117)  ·  Myeloproliferative Disorders (112)  ·  Neoplasms by Histologic Type (101)  ·  Leukemia, Myeloid (94)  ·  Pathologic Processes (89)  ·  Pathological Conditions, Signs and Symptoms (89)  ·  Disease Attributes (88)  ·  Chronic Disease (86)  ·  Neoplasms by Site (86)  ·  Hemorrhagic Disorders (84)  ·  Immune System Diseases (74)  ·  Immunoproliferative Disorders (73)

Interventions

ruxolitinib (43)  ·  fludarabine phosphate (15)  ·  Cyclophosphamide (13)  ·  Peripheral Blood Stem Cell Transplantation (12)  ·  Tacrolimus (11)  ·  Busulfan (10)  ·  Azacitidine (9)  ·  Filgrastim (8)  ·  Methotrexate (7)  ·  Mycophenolic Acid (7)  ·  Sirolimus (7)  ·  Whole-Body Irradiation (7)  ·  fludarabine (7)  ·  11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (6)  ·  Cyclosporine (6)

Sponsors

Incyte Corporation (12)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (9)  ·  M.D. Anderson Cancer Center (8)  ·  National Cancer Institute (NCI) (7)  ·  Novartis Pharmaceuticals (7)  ·  City of Hope Medical Center (6)  ·  Case Comprehensive Cancer Center (4)  ·  John Mascarenhas (4)  ·  AbbVie (3)  ·  Bristol-Myers Squibb (3)  ·  Fred Hutchinson Cancer Center (3)  ·  Mayo Clinic (3)  ·  Northwestern University (3)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3)  ·  Suzhou Zelgen Biopharmaceuticals Co.,Ltd (3)

Countries

United States (156)  ·  Italy (27)  ·  Germany (24)  ·  Australia (21)  ·  France (21)  ·  United Kingdom (18)  ·  Canada (17)  ·  Spain (16)  ·  China (15)  ·  Belgium (8)  ·  Japan (8)  ·  Netherlands (8)  ·  South Korea (8)  ·  Poland (6)  ·  Bulgaria (4)

Top investigators

Ayalew Tefferi, MD (5)  ·  Ronald Hoffman, MD (5)  ·  John Mascarenhas, MD (4)  ·  Fred Zheng, M.D. (2)  ·  Haris Ali (2)  ·  Jorge Cortes, MD (2)  ·  Kenneth G. Lucas, MD (2)  ·  Kyoo H. Lee, MD (2)  ·  Martha Wadleigh, MD (2)  ·  Richard K. Burt, MD (2)  ·  Ruben Mesa, MD (2)

Results publications

PMID 31527168, PMID 15570084, PMID 17562873, PMID 20843246, PMID 21742281, PMID 22259028, PMID 22547163, PMID 22718840, PMID 23682558, PMID 23993427, PMID 24002496, PMID 24355079, PMID 24474568, PMID 24530972, PMID 25563429, PMID 25762180, PMID 26210442, PMID 26853648, PMID 27479177, PMID 27634203, PMID 27736729, PMID 27931243, PMID 28934680, PMID 29515114, PMID 29544547, PMID 30249277, PMID 30562587, PMID 31778911, PMID 32325461, PMID 32396615, PMID 32634234, PMID 33635333, PMID 33718228, PMID 34581764, PMID 36105914, PMID 36125208, PMID 36594185, PMID 36881782, PMID 37290996, PMID 37422688, PMID 37530627, PMID 38118249, PMID 38259250, PMID 39863139, PMID 39924599, PMID 40241543, PMID 40334082, PMID 40643151, PMID 40752760, PMID 40919483

NIH funding

2018 (3), 2019 (3), P01CA108671 (3), P30CA033572 (3), 2017 (2), 2023 (2), P30CA006973 (2), P30CA015083 (2), U01CA062491 (2), 2014 (1), 2015 (1), 2025 (1), P01CA015396 (1), P01CA229092 (1), P30CA014599 (1)